The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations
Cancers · 28.01.2023 · 15 (3) · 808
DOI: 10.3390/cancers15030808 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 28.01.2023. Verfasst von Brian S Finkelman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY 14620, USA. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 193 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The 1983 discovery of a mouse monoclonal antibody—the Ki-67 antibody—that recognized a nuclear antigen present only in proliferating cells represented a seminal discovery for the pathologic assessment of cellular proliferation in breast cancer and other solid tumors. Cellular proliferation is a central determinant of prognosis and response to cytotoxic chemotherapy in patients with breast cancer, and since the discovery of the Ki-67 antibody, Ki-67 has evolved as an important biomarker with both prognostic and predictive potential in breast cancer. Although there is universal recognition among the international guideline recommendations of the value of Ki-67 in breast cancer, recommendations for the actual use of Ki-67 assays in the prognostic and predictive evaluation of breast cancer remain mixed, primarily due to the lack of assay standardization and inconsistent inter-observer and inter-laboratory reproducibility. The treatment of high-risk ER-positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer with the recently FDA-approved drug abemaciclib relies on a quantitative assessment of Ki-67 expression in the treatment decision algorithm. This further reinforces the urgent need for standardization of Ki-67 antibody selection and staining interpretation, which will hopefully lead to multidisciplinary consensus on the use of Ki-67 as a prognostic and predictive marker in breast cancer. The goals of this review are to highlight the historical evolution of Ki-67 in breast cancer, summarize the present literature on Ki-67 in breast cancer, and discuss the evolving literature on the use of Ki-67 as a companion diagnostic biomarker in breast cancer, with consideration for the necessary changes required across pathology practices to help increase the reliability and widespread adoption of Ki-67 as a prognostic and predictive marker for breast cancer in clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY 14620, USA.
ORCID-Profile: Brian S Finkelman, Bradley M Turner
Zitieren
APA
Finkelman, B. S., Zhang, H., Hicks, D. G., & Turner, B. M. (2023). The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations. Cancers, 15(3), 808. https://doi.org/10.3390/cancers15030808
Vancouver
Finkelman BS, Zhang H, Hicks DG, Turner BM. The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations. Cancers. 2023;15(3):808. doi:10.3390/cancers15030808
BibTeX
@article{Finkelman2023,
author = {Finkelman, Brian S and Zhang, Huina and Hicks, David G and Turner, Bradley M},
title = {The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations},
journal = {Cancers},
year = {2023},
volume = {15},
number = {3},
pages = {808},
doi = {10.3390/cancers15030808}
}
EUVIMED